MedaSystems – a developer of the only purpose-built pharma-physician network to provide patients with access to pre-approval medicine – recently announced the completion of a seed funding round. Participants in the round include a mix of strategic angel and health tech venture investors with prior track records of founding and funding successful SaaS health companies, including Young Sohn, a founder of Veeva Systems, Vlocity, and Nomadic Systems; nina.capital, a specialist healthtech venture capital fund based in Barcelona; and members of the management team.
MedaSystems’ SaaS platform streamlines collaboration between medical affairs, clinical operations, regulatory and shipping teams internally, and physicians and their staff externally – enabling the rapid processing of treatment inquiries and capture of real-world data.
The company’s platform provides significant benefits to various stakeholders:
— Sponsors (pharmaceutical manufacturers) gain significant processing speed and efficiency. And the platform enables the capture of real-world data which speeds drug discovery, expedites regulatory submission and informs the design of more effective clinical trials. Users can create forms to capture de-identified, real-world data. Plus, the flexible data architecture and workflow means that sponsors can run a variety of programs on the platform, from Expanded or Managed Access to Post-Trial Access programs and Investigator Initiated Study requests, supporting all aspects of patient treatment outside of Clinical Trials.
— Physician workload is reduced with the ability to rapidly submit applications for patients who have no other treatment options and cannot participate in clinical trials. And the platform provides greater visibility by allowing physicians to work with their staff and pharmacists to understand where inquiries stand, the ability to request treatment, and provide treatment updates.
“This funding supports our goal of making life saving treatments more easily available to patients and physicians and supporting research and development of new therapies. These funds allow us to support vital real-world data capture, automation, and machine learning capabilities.”
— Fiona Smythe, CEO of MedaSystems